SCHEDULE: FMR LLC Discloses 5.7% Stake in NewAmsterdam Pharma

FMR LLC and Abigail P. Johnson have reported a 5.7% beneficial ownership stake in NewAmsterdam Pharma Company NV's common stock as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 6,412,984 shares of NewAmsterdam Pharma Company NV common stock.
• This ownership represents 5.7% of the total outstanding common stock of NewAmsterdam Pharma Company NV.
• The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of the issuer.
• FMR LLC is classified as a parent holding company, and Abigail P. Johnson, an individual, is a Director, Chairman, and Chief Executive Officer of FMR LLC.
• The filing includes a Rule 13d-1(k)(1) agreement, indicating a joint filing by the reporting persons.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies significant institutional interest and a substantial stake taken by a reputable asset manager, FMR LLC, in NewAmsterdam Pharma Company NV.

Positives

• Significant institutional investment from FMR LLC, a major asset manager, indicates a notable level of confidence in NewAmsterdam Pharma Company NV.
• The reported stake is held for investment purposes in the ordinary course of business, suggesting a stable, long-term interest rather than an activist position.

Future Outlook

Not applicable, as this filing is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G often signal increased investor interest in the pharmaceutical or biotechnology sector, particularly for companies like NewAmsterdam Pharma. The involvement of a major asset manager like FMR LLC can attract further attention from other institutional and retail investors, potentially impacting market perception and liquidity.

Stakeholder Impact

• Shareholders: Increased confidence due to significant institutional backing from FMR LLC, potentially leading to improved market perception and liquidity.
• Company Management: Validation of the company's strategy and potential for long-term stability from a significant, non-activist investor.

Key Dates

Recommendation

The filing indicates a significant institutional stake by FMR LLC, a major asset manager, which can be interpreted as a vote of confidence in NewAmsterdam Pharma Company NV. While this is a positive signal, the filing itself does not provide operational or financial performance data to warrant a 'buy' or 'strong buy' recommendation. For existing investors, this news supports holding the stock, as it suggests long-term institutional interest without immediate intent to influence control.

Keywords

NewAmsterdam Pharma, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Pharmaceuticals, Biotech